Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer
Not yet recruitingOBSERVATIONAL
Enrollment
66
Participants
Timeline
Start Date
April 20, 2025
Primary Completion Date
October 20, 2025
Study Completion Date
October 20, 2027
Conditions
Minimal Residual DiseasePancreatic Cancer Resectable
Trial Locations (1)
Unknown
Zhongshan Hospital, Shanghai, Shanghai
All Listed Sponsors
lead
Shanghai Zhongshan Hospital
OTHER
NCT06941987 - Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer | Biotech Hunter | Biotech Hunter